Zealand Pharma Submits Marketing Authorization Application To EMA For Dasiglucagon

(RTTNews) - Zealand Pharma A/S (ZEAL) has submitted a Marketing Authorization Application to the European Medicines Agency for dasiglucagon injection for the treatment of severe hypoglycemia in adults, adolescents, and children aged 6 years and over with diabetes mellitus.

Dasiglucagon was approved by the FDA in March 2021 under the brand name Zegalogue. In September 2022, Zealand entered into a global license and development agreement with Novo Nordisk A/S to commercialize Zegalogue. Zegalogue is a registered trademark of Novo Nordisk A/S. Zealand is eligible to receive up to 265 million Danish kroner in development, regulatory, manufacturing and sales-based milestones, as well as tiered royalties on worldwide net sales of Zegalogue to be marketed by Novo Nordisk.

For More Such Health News, visit rttnews.com.